Oncolytics Biotech (ONCY) Accounts Payables (2009 - 2025)

Oncolytics Biotech (ONCY) has 17 years of Accounts Payables data on file, last reported at $3.5 million in Q4 2025.

• On a quarterly basis, Accounts Payables rose 2.15% year-over-year to $3.5 million in Q4 2025; TTM through Dec 2025 was $3.5 million, a 2.15% increase from a year earlier, with the FY2025 full-year figure at $3.5 million, up 363.49% from the prior year.
• Accounts Payables for Q4 2025 stood at $3.5 million, down from $5.2 million in the prior quarter.
• Over the last five years, Accounts Payables for ONCY reached as high as $5.2 million in Q3 2025 and fell as low as $1.5 million in Q1 2021.
• Historically, Accounts Payables has averaged $2.6 million across 5 years, with a median of $2.6 million in 2022.
• Across the five-year window, Accounts Payables tumbled 45.44% in 2021 and soared 112.39% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $1.6 million in 2021, then soared by 70.5% to $2.7 million in 2022, then declined by 2.42% to $2.6 million in 2023, then jumped by 30.74% to $3.4 million in 2024, then gained by 2.15% to $3.5 million in 2025.
• Per Business Quant data, the three most recent Accounts Payables figures were $3.5 million in Q4 2025, $5.2 million in Q3 2025, and $3.8 million in Q2 2025.